Skip to content

Effects of Nutritional Intervention With Fish-derived Lipids in Improving Antiviral Immunity

Evaluation of the Effectiveness of Nutritional Intervention With Fish-derived Lipids in Improving Antiviral Immunity in Healthy People

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05502172
Enrollment
26
Registered
2022-08-16
Start date
2022-11-18
Completion date
2024-07-12
Last updated
2024-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutrition, Healthy

Keywords

fish oil, antiviral immune reponse

Brief summary

The aim of the study is to evaluate the effects of fish-derived lipids on antiviral immunity in healthy individuals. The study will be conducted on a group of 30 healthy volunteers recruited at the Department of Periodontology and Oral Diseases of the Medical University of Lodz. These people will take a composition of fish-derived oils (BioMarine®Medical Immuno & Neuro Lipids) at a dose of 0.5 ml / kg body weight per day in two / three divided doses for 90 days. BioMarine®Medical Immuno & Neuro Lipids is food for special medical purposes. At baseline and after 90 days, blood samples will be taken from the test subjects in order to evaluate the selected parameters of antiviral immunity.

Detailed description

The proposed clinical trial involving a nutritional intervention aims to assess the effect of a composition of fish oils containing, inter alia, WWKT omega-3 EPA and DHA, alkylglycerols and squalene on selected parameters of antiviral immunity in healthy people. The proposed daily dose of BioMarine®Medical Immuno & Neuro Lipids is 0.5 ml / kg b.w., which in practice for a person weighing 60 kg will mean a daily consumption of 30 mL of oil (including 1.6 g EPA, 9.1 g DHA, 2 5 g of alkylglycerols and 2.6 g of squalene). At baseline, 15 ml of blood will be drawn in order to determine the parameters of the antiviral response. The following immunological parameters will be tested: 1. NK cell activity using a mixed culture of PBMC with target cells (ability to inhibit tumor cell proliferation) assessed by flow cytometry. 2. Absolute number and percentage of NK cells (CD16 + CD56 +), cytotoxic (CD8 +), helper (CD4 +) lymphocytes, B (CD19 +) lymphocytes in the total pool of peripheral blood mononuclear cells (PBMC) by flow cytometry. 3. Ability of isolated PBMCs to synthesize INF-α, INF-β, INF-γ, IL-6 and TNF without and after polyclonal stimulation (PHA) and SARS-CoV-2 proteins (nucleocapside protein, SARS-CoV-2 spike protein ) in 42 h culture based on the determination of the level of protein released into the culture fluid and on the basis of mRNA expression for these factors. Analysis of PBMC post-culture supernatants (CBA technique with flow cytometer and gene expression analysis by qPCR). 4. Analysis of the composition of serum lipids and in PBMC lyophilisates after culture. Blood sampling will be repeated after 90 days in order to determine the influence of the fish oils on the tested parameters.

Interventions

DIETARY_SUPPLEMENTfish oil

healthy individuals will be taking the composition of fish-deraivd oils BioMarine®Medical Immuno & Neuro Lipids at a dose of 0.5 ml / kg body weight per day in two / three divided doses for 90 days.

Sponsors

Marinex International Sp. z o.o.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* absence of systemic diseases; * no medications taken on a regular basis; * correct body weight in relation to height - 18.5 ≤ BMI ≤ 24.9

Exclusion criteria

* lack of consent the patient'sto the examination. * pregnant and lactating women; * smokers or non-smokers for less than 5 years; * any vaccinations in the period shorter than 1 month before the start of the study or planned during the study; * lack of declaration on reducing fats in the diet and avoiding highly processed fats and fried products.

Design outcomes

Primary

MeasureTime frameDescription
Change in peripheral blood NK cell activitybaseline, 90 daysNK cell activity using a mixed culture of PBMC with target cells (ability to inhibit tumor cell proliferation) assessed by flow cytometry.
Change in the number and percentage of peripheral blood NK cells, CD8 cells, CD4 cells, CD19 cellsbaseline, 90 daysAbsolute number and percentage of NK cells (CD16 + CD56 +), cytotoxic (CD8 +), helper (CD4 +) lymphocytes, B (CD19 +) in the total pool of peripheral blood mononuclear cells (PBMC) by flow cytometry.
Change in the production of cytokines (INF-α, INF-β, INF-γ, IL-6 and TNF) by peripheral blood mononuclear cellsbaseline, 90 daysAbility of isolated PBMCs to synthesize INF-α, INF-β, INF-γ, IL-6 and TNF without and after polyclonal stimulation (PHA) and SARS-CoV-2 proteins (nucleocapside protein, SARS-CoV-2 spike protein ) in 42 h culture based on the determination of the level of protein released into the culture fluid and on the basis of mRNA expression for these factors. Analysis of PBMC post-culture supernatants (CBA technique with flow cytometer and gene expression analysis by qPCR).

Secondary

MeasureTime frameDescription
Change in serum lipid contentbaseline, 90 daysAnalysis of lipid composition using gas/spectrum chromotography
Change in in lipid content in PBMC lyophilisatesbaseline, 90 daysAnalysis of lipid composition using gas/spectrum chromotography

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026